It sounds to me like AFFY will be come a shell company under Takeda receiving a stream of royalty payments for a reintroduced O. This sounds like an absorption rather than a bankruptcy. What would worry me would be if Takeda decided to just sit on reintroducing O causing the collapse of AFFY pps and wait till they need not pay royalties. I would think there is more to gain by reintroducing O economically for them though. From that perspective AFFY may never go bk as long as Takeda is solid.
Sailor. I think it's in Takeda's best interest to get O back on the market asap. Don't forget that Affy still owns the patents and TBG is there to get the best value for shareholders. The buy out would be good short term but I am inclining towards a shell company receiving royalties every year and the monies being distributed to the share holders. This is a billion dollar drug and is a cash cow for Takeda.